产品
编 号：F196303
分子式：C22H21Cl2N7O
分子量：470.35
分子式：C22H21Cl2N7O
分子量：470.35
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1632250-50-0
产品详情
生物活性：
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
体内研究：
PF-06446846 (oral gavage; 5-50 mg/kg/day for 14 days) lowers plasma PCSK9 in a dose-dependent manner and lowers total cholesterol levels.Animal Model:Male Sprague-Dawley (Crl:CD [SD] rats, 6-8 wk old at initiation of dosing)
Dosage:5, 15, and 50 mg/kg
Administration:Oral gavage; daily for 14 days
Result:Lowered plasma PCSK9 in a dose-dependent manner and lowered total cholesterol levels.
体外研究：
PF-06446846 inhibits the secretion of PCSK9 by Huh7 cells with an IC50 of 0.3 μM.
PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
体内研究：
PF-06446846 (oral gavage; 5-50 mg/kg/day for 14 days) lowers plasma PCSK9 in a dose-dependent manner and lowers total cholesterol levels.Animal Model:Male Sprague-Dawley (Crl:CD [SD] rats, 6-8 wk old at initiation of dosing)
Dosage:5, 15, and 50 mg/kg
Administration:Oral gavage; daily for 14 days
Result:Lowered plasma PCSK9 in a dose-dependent manner and lowered total cholesterol levels.
体外研究：
PF-06446846 inhibits the secretion of PCSK9 by Huh7 cells with an IC50 of 0.3 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备